Toronto, Ontario--(Newsfile Corp. - December 12, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company pioneering light, radiation, sound and drug-activated therapeutics for the treatment of cancer, bacteria and viruses, has commenced a non-brokered private placement of units of the Company ("Units") to raise up to $CAN 2,000,000 ("Offering"). In the Offering, each Unit is priced at $CAN 0.17 and consists of one common share of the Company ("Common Share") and one Common Share purchase warrant ("Warrant").

Ryder System's long-time leader, Robert Sanchez, is retiring early next year as chief executive of the logistics and transportation company.

MIAMI--(BUSINESS WIRE)--Ryder System, Inc. (NYSE: R) announces Chairman and Chief Executive Officer (CEO) Robert E. Sanchez, 60, will retire on March 31, 2026. As part of the succession plan approved by the company's board of directors, Ryder's President and Chief Operating Officer John J. Diez, 54, will assume the chief executive officer role of the fully integrated logistics and transportation company, effective March 31, 2026. Diez was also elected to the company's board of directors, effect.

The collaboration highlights Zomedica's commitment to expanding pet wellness education as Assisi Loop technology is featured in the highly anticipated movie Merv now available on Prime Video ANN ARBOR, MI / ACCESS Newswire / December 11, 2025 / Zomedica Corp. (OTCQB:ZOMDF) ("Zomedica" or the "Company"), an animal health company offering innovative diagnostic and therapeutic devices for equine and companion animals, is thrilled to announce that its Assisi ® and Calmer Canine® products are featured in the new romantic comedy Merv, available now on Prime Video. Zomedica Brings Real Pet Wellness Technology to the Big Screen In an exciting collaboration with Prime Video, Zomedica's Assisi and Calmer Canine technologies are featured in Merv, a feel-good romantic comedy starring Zooey Deschanel and Charlie Cox.

Launch targets $16 billion SGLT-2 inhibitor market that serves 33 million type II diabetics in the US, many of whom are uninsured and underinsured and whose out-of-pocket costs exceed Brenzavvy's cash price Proprietary EinsteinRx™ artificial intelligence pharmacy platform empowers the 6,500+ pharmacies in the Wellgistics Pharmacy Network to educate patients and providers on the advantages of Brenzavvy vs. Jardiance® and other SGLT-2 inhibitors Reduced out-of-pocket costs for patients, paired with a patient-education revenue opportunity for pharmacists, are designed to support broader market access to Brenzavvy and enhance the overall care experience Launch establishes a new model for next-generation reformulated drugs that offer patient-specific product advantages compared with entrenched market leaders TAMPA, FL / ACCESS Newswire / December 8, 2025 / Wellgistics Health, Inc. ("Wellgistics") (NASDAQ:WGRX), a health information technology leader, integrating proprietary pharmacy dispensing optimization artificial intelligence platform EinsteinRx ™ into its patented blockchain-enabled smart contracts platform PharmacyChain™, today announced that it has begun the commercial launch of diabetes prescription drug Brenzavvy® to its network of 6,500 independent pharmacies (the "Wellgistics Pharmacy Network") that primarily target patients in rural communities where there is often an increased incidence of diabetes.

Ryder System, Inc. (R) Presents at Goldman Sachs Industrials and Materials Conference 2025 Transcript

~ Procedures Completed in Various Spine Centers of Excellence Throughout the Country Including Florida, Arizona, Ohio, and Texas ~ ~ SImmetry+ combines 3D-printed titanium implants, a robust joint decorticator, and a streamlined bone graft delivery system to offer treatment solutions aligned with established fusion principles ~ ~ Immediate revenue impact opportunity while significantly advancing Tenon's competitive position in redefining SI joint fusion with a multi-approach portfolio in rapidly expanding sacro-pelvic market ~ LOS GATOS, CA / ACCESS Newswire / December 4, 2025 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon" or the "Company"), a company redefining care for patients suffering from sacro-pelvic disorders, today announced the completion of the first clinical procedures utilizing the Company's new SImmetry+ SI Joint Fusion System. Ali Araghi, DO, Orthopedic Spine Surgeon in Phoenix, Arizona, Brian Fiani, DO Board Certified Neurosurgeon in Tampa, FL.

Newest assay expands TRUFORMA market opportunity by building on endocrinology foundation to address reproductive health in the equine segment ANN ARBOR, MI / ACCESS Newswire / December 4, 2025 / Zomedica Corp. (OTCQB:ZOMDF) ("Zomedica" or the "Company"), an animal health company offering innovative point-of-care diagnostic and therapeutic device products for equine and companion animals, today announced the expansion of its TRUFORMA platform with the launch of its equine progesterone assay, designed as a powerful reproductive management tool to support breeding programs, pregnancy monitoring, and improved outcomes for horse owners. "By introducing the TRUFORMA Progesterone assay, we are extending the TRUFORMA platform's utility from endocrine diagnostics into reproductive health, a domain of immense importance to equine veterinarians and breeders," said Michael Mockler, Senior Product Manager at Zomedica.

R's rising operating costs, weaker earnings estimates and soft share performance highlight mounting pressures for the company.

VANCOUVER, BC / ACCESS Newswire / December 2, 2025 / StimCell Energetics Inc. (OTCQB:STME) ("StimCell" or the "Company"), a biotech pioneer targeting cellular energy to enhance wellness, anti-aging, and longevity, today announced the signing of a service agreement with the St. Boniface Hospital Albrechtsen Research Centre, affiliated with the University of Manitoba, and Principal Investigator, Professor Paul Fernyhough. This collaboration will explore the effects of StimCell's proprietary eBalance® device on mitochondrial function in cultured sensory neurons to further define the physiological action of microcurrents.